Feb 2, 2007 by Brian GormanKraft's Ever-Shifting MenuRecent anemic results belie more promising future prospects.
Feb 1, 2007 by Brian GormanBoeing's Continuing ClimbThe company can consolidate its lead if it overcomes some challenges.
Jan 31, 2007 by Brian GormanMerck's Special InterestMerck is likely to succeed in getting states to mandate HPV vaccination.
Jan 25, 2007 by Brian GormanCovance Stays SolidDespite a run-up in the stock, Covance may be in for yet another solid year.
Jan 22, 2007 by Brian GormanSouthwest's Declining Edge?Past advantages in fuel and labor expenses appear to be on the wane.
Jan 10, 2007 by Brian GormanCalifornia Pizza Rising?The company's EPS forecast is enticing, but is it enough to buy on?
Jan 4, 2007 by Brian GormanMonsanto's Bigger Harvest?High corn prices could allow Monsanto to raise seed prices and improve margins.
Jan 3, 2007 by Brian GormanGM's Malibu MakeoverWhile it's no trailblazer, this new car model shows that the company is paying attention to the right things.
Jan 3, 2007 by Brian GormanGeneral Mills Rethinks TrixThe rise and fall of the company's low-sugar kids' cereals illustrates the pitfalls of responding hastily to media frenzies.
Dec 19, 2006 by Brian GormanNovartis Cuts in Line at the DrugstoreConsolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure.
Dec 11, 2006 by Brian GormanDefense Contractors Under Attack?The stage could be set for budget shifts that will hurt some defense contractors and help others.
Dec 5, 2006 by Brian GormanMonsanto Needs to CharmThe company has to confront concerns over genetically modified foods soon if it hopes to keep growing.
Dec 4, 2006 by Brian GormanYahoo!'s New Camera CrewA new feature allows users the chance to make the news.
Nov 28, 2006 by Brian GormanMore Political Ire for Wal-Mart?Christian conservatives could have had something to do with Wal-Mart's November weakness.
Nov 20, 2006 by Brian GormanHospira's Bold MoveThe drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff.
Nov 13, 2006 by Brian GormanPolo's Next HurdleThe luxury goods purveyor looks poised to finish strong in fiscal 2007, but keeping up the pace will present a challenge.
Nov 10, 2006 by Brian GormanAlbany Molecular Plays the OddsWill more investment in drug development hurt profitability?
Nov 7, 2006 by Brian GormanCharles River Inches ForwardThe company is not out of the woods yet, but some positive signs are emerging.
Nov 6, 2006 by Brian GormanNovartis' China GambitNovartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore.
